Compare MDGL & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | BIO |
|---|---|---|
| Founded | 2011 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.1B |
| IPO Year | 2005 | 1994 |
| Metric | MDGL | BIO |
|---|---|---|
| Price | $437.29 | $367.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 3 |
| Target Price | ★ $685.78 | $335.00 |
| AVG Volume (30 Days) | ★ 262.9K | 221.8K |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ N/A | N/A |
| Revenue | $180,133,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | $59.57 | N/A |
| Revenue Next Year | $38.84 | $2.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.65 |
| 52 Week Low | $393.61 | $236.73 |
| 52 Week High | $615.00 | $396.23 |
| Indicator | MDGL | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 29.07 | 52.06 |
| Support Level | $416.21 | $358.85 |
| Resistance Level | $546.29 | $391.87 |
| Average True Range (ATR) | 18.02 | 12.10 |
| MACD | -1.58 | -0.04 |
| Stochastic Oscillator | 1.57 | 49.59 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.